A new MoU between the Centre for Cellular and Molecular Platforms (C-CAMP) and Imperial College London has paved the way for deepening India-UK ties in the life sciences sector.
India has launched its first repository of data on major psychiatric disorders, CALM-Brain, in Bengaluru. This initiative aims to systematically document details of patients with mental illness to improve diagnosis and treatment.
Union Minister Jitendra Singh inaugurated a new biotechnology facility and dedicated a national facility for recombinant cells and sensors at the Rajiv Gandhi Centre for Biotechnology in Thiruvananthapuram, highlighting India's focus on biotechnology and its potential for economic growth.
'AdFalciVax may offer advantages such as broader protection and a lower risk of immune evasion compared to existing single-stage malaria vaccines.'
Shukla will be the second Indian to travel to space four decades after Rakesh Sharma's iconic spaceflight onboard Russia's Soyuz spacecraft in 1984.
Indian astronaut Shubhanshu Shukla and three others were getting ready for their journey to the International Space Station on board SpaceX's Falcon-9 rocket that is scheduled to blast off from the Kennedy Space Centre (KSC) in Florida on Tuesday evening.
Indian astronaut Shubhanshu Shukla and three others are set to embark on the Axiom Space's fourth human spaceflight from National Aeronautics and Space Administration's (NASA) Kennedy Space Centre in Florida on June 10 and are likely to dock at the International Space Station on June 11 at about 10 pm IST, after a nearly 28-hour journey.
Indian astronaut Shubhanshu Shukla stands on the cusp of history as he prepares to set off on a space odyssey, marking India's return to space flight 41 years after his idol Rakesh Sharma orbited the earth for eight days as part of Soviet Union's Interkosmos programme.
SpaceX's Falcon-9 rocket was scheduled to blast off from the Kennedy Space Centre in Florida on Tuesday evening.
The Indian Diaspora has been able to carve a niche in their adopted countries as a result of their talent, perseverance and hardworking nature, asserts Rup Narayan Das.
'iNCOVACC' is priced at Rs 800 for private markets and at Rs 325 for supplies to the government of India and state governments.
Biological E has received approval for conducting phase II/III human clinical trial of COVID-19 vaccine candidate Corbevax on children above five years and adolescents, the Department of Biotechnology (DBT) said on Friday.
This is the world's first DNA-based vaccine against the coronavirus, and this three-dose vaccine when injected produces the spike protein of the SARS-CoV-2 virus and elicits an immune response, which plays a vital role in protection from the disease as well as viral clearance
India's first indigenously developed quadrivalent Human Papilloma Virus (HPV) vaccine for the prevention of cervical cancer will be launched in a few months and made available to the people in an affordable price range of Rs 200-400, Serum Institute of India CEO Adar Poonawalla said on Thursday.
The minister will review the COVID-19 situation at 11:30 am on Wednesday 'considering the international scenario', they said.
Efforts are being ramped up for massive production of vaccines and make them available in the shortest possible time, a top government official said on Wednesday, stressing that India currently has a promising pipeline of four-five Covid-19 vaccine candidates, while three have already been approved for emergency use.
India and the US on Friday said they have started talks to put in place a strategic framework for human space flight by year-end as they plan to send an Indian astronaut to the International Space Station in 2024.
The novel mRNA vaccine candidate, HGCO19, is supported with seed grant under the Ind-CEPI mission of the Department of Biotechnology. The mRNA vaccines do not use the conventional model to produce immune response. Instead, they carry molecular instructions to make the protein in the body through a synthetic RNA of the virus.
She said the grant does not cover the actual cost of vaccine and distribution expenses, which will be made separately as and when the vaccine is available.
The tenure of the incumbent AIIMS director, Dr Randeep Guleria, which was set to end on March 24, was extended by three months.
The Centre has taken a major step towards increasing efficiency in decision-making by empowering joint secretaries to report to secretaries directly, officials said on Wednesday.
The vaccine would not have production scalability issues unlike Covaxin, Bharat Biotech's COVID-19 virus vaccine.
The company said it had conducted two separate trials for its intranasal Covid vaccine, one as a primary dose schedule and another as a booster dose, for subjects who have been double vaccinated with the two commonly administered Covid vaccines in India.
The production of Covaxin will increase from the current 10 million doses per month to 60 million-70 million by July-August.
According to government sources, the matter was discussed by the national expert group on vaccine administration for COVID-19 in its last meeting held on August 22.
The DCGI's nod came after the subject expert committee on COVID-19 of the CSDCO last week recommended granting emergency use authorisation to Covovax for the age group of 7 to 11 years.
Several professors of Jawaharlal Nehru University and other institutions have accused a former JNU employee of duping them of crores of rupees promising them homes on a Delhi Development Authority (DDA) plot under a housing development scheme which was never there.
Both manufacturers have sought funds in excess of Rs 150 crore under the department of biotechnology's Mission Covid Suraksha scheme. Announced last November, the scheme has an outlay of Rs 900 crore to help develop Covid vaccines, from the clinical development stage to setting up production sites.
A senior health official said the probe will find out how the teenager was given the shot even though the government is yet to roll out any anti-COVID 19 vaccination programme for minors.
According to the sources, there are limited prospects of J&J exporting its vaccine from the US to other countries in the near future and the "entire production" at the BE facilities in India, beginning July/August, will be handed over to the pharma giant under a contract between the companies.
He urged people not to panic and clarified that there was no change in the guidelines for international air travel so far.
"The COVID-19 cases are rising, but hospitalization and deaths are still less," said sources.
The Indian SARS-CoV-2 Genomics Consortium is closely tracking the new variant of COVID-19 called B.1.1.529 and its presence has not been detected in the country yet, officials said on Friday.
The Serum Institute of India, Bharat Biotech and Pfizer have applied to the DCGI seeking emergency use authorisation for their COVID-19 vaccine candidates and are awaiting approval.
Russia's Sputnik V vaccine is currently being manufactured in India by Dr Reddy's Laboratories.
Phase-I clinical trials have revealed "excellent safety" of the two candidate vaccines indigenously developed by Bharat Biotech in collaboration with Indian Council of Medical Research and Cadila Healthcare Ltd and their immunogenicity testing is now in progress, minister of state for health Ashwini Choubey informed the Rajya Sabha on Tuesday.
During the meeting, scheduled to be held through video conference at 6 pm on Tuesday, the Department of Biotechnology will make a presentation and also coordinate with all the participants, sources added.
The first nasal vaccine against COVID-19, developed by Bharat Biotech, has received regulator's nod for conducting phase 2 clinical trials, the Department of Biotechnology said on Friday.
When several opposition MPs expressed their desire to ask questions about the Centre's vaccination policy such as increasing the gap between two doses, the BJP MPs strongly opposed it and few of them even demanded postponement of the meeting and walked out, the sources said.
The Union health ministry on Wednesday dismissed media reports claiming there was dissent from technical experts about increasing the gap between two Covishield doses and said the decision was based on scientific reason about the behaviour of adenovector vaccines.
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances